Therapeutic effect of ouabagenin, a novel liver X receptor agonist, on atherosclerosis in nonalcoholic steatohepatitis in SHRSP5/Dmcr rat model
Canadian Journal of Physiology and Pharmacology · 2023
DOI: 10.1139/cjpp-2022-0532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2023. Verfasst von Shusei Yamamoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Atherosclerosis. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
The liver X receptor (LXR) can enhance cholesterol transporters, which could remove excess cholesterol from foam cells in atheromas. LXR has two subtypes: LXRα, which aggravates hepatic lipid accumulation, and LXRβ, which does not. In 2018, ouabagenin (OBG) was reported as a potential LXRβ-specific agonist. We aimed to examine whether OBG specifically affects LXRβ in nonalcoholic steatohepatitis (NASH); it did not aggravate hepatic steatosis and can suppress the development of atherosclerosis. SHRSP5/Dmcr rats fed a high-fat and high-cholesterol diet were divided into four groups as follows: (I) L-NAME group, (II) L-NAME/OBG group, (III) OBG (−) group, and (IV) OBG (+) group. All groups’ rats were intraperitoneally administered L-NAME. The L-NAME/OBG group’s rats were intraperitoneally administered OBG and L-NAME simultaneously. After L-NAME administration, the OBG (+) group’s rats were administered OBG, while the OBG (−) group’s rats were not. Although all rats developed NASH, OBG did not exacerbate steatosis (L-NAME/OBG and OBG (+) groups). In addition, endothelial cells were protected in the L-NAME/OBG group and foam cells in the atheroma were reduced in the OBG (+) group. OBG is an LXRβ-specific agonist and has a potential therapeutic effect on atherosclerosis without developing lipid accumulation in the liver.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan.
- Department of Medical Technology, Graduate School of Health Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan.
- Department of Medical Technology, Ehime Prefectural University of Health Sciences, 543 Takoda, Tobe-cho, Iyo-gun, Ehime 791-2101, Japan.
- Department of Medical Technology, Faculty of Health Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama 700-8558, Japan.
- School of Pharmaceutical Sciences, Wakayama Medical University, 25-1 Shichibancho, Wakayama-shi, Wakayama 640-8156, Japan.
- Department of Chemistry, Graduate School of Life Science, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai-shi, Miyagi 980-8578, Japan.
ORCID-Profile: Shogo Watanabe
Zitieren
APA
Yamamoto, S., Sato, I., Fujii, M., Kakimoto, M., Honma, K., Kirihara, S., Nakayama, H., Fukuoka, T., Tamura, S., Ueda, M., Hirohata, S., & Watanabe, S. (2023). Therapeutic effect of ouabagenin, a novel liver X receptor agonist, on atherosclerosis in nonalcoholic steatohepatitis in SHRSP5/Dmcr rat model. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2022-0532
Vancouver
Yamamoto S, Sato I, Fujii M, Kakimoto M, Honma K, Kirihara S, et al. Therapeutic effect of ouabagenin, a novel liver X receptor agonist, on atherosclerosis in nonalcoholic steatohepatitis in SHRSP5/Dmcr rat model. Canadian Journal of Physiology and Pharmacology. 2023. doi:10.1139/cjpp-2022-0532
BibTeX
@article{Yamamoto2023,
author = {Yamamoto, Shusei and Sato, Ikumi and Fujii, Moe and Kakimoto, Mai and Honma, Koki and Kirihara, Sora and Nakayama, Hinako and Fukuoka, Taketo and Tamura, Satoru and Ueda, Minoru and Hirohata, Satoshi and Watanabe, Shogo},
title = {Therapeutic effect of ouabagenin, a novel liver X receptor agonist, on atherosclerosis in nonalcoholic steatohepatitis in SHRSP5/Dmcr rat model},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2023},
doi = {10.1139/cjpp-2022-0532}
}
EUVIMED